Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tumor suppressor acts as oncogene in some cancers

28.10.2010
Researchers at Mayo Clinic in Florida have found that a molecule long believed to be a beneficial tumor suppressor — and thus a potential cancer drug target — appears to act as an oncogene in some lethal brain tumors.

The protein, epithelial cadherin (E-cadherin), is known for its ability to keep cancer cells glued together, preventing them from breaking away and metastasizing. But, based on their findings, published online in PLoS ONE, the scientists suggest E-cadherin can also function as an oncogene in some cancers. An oncogene helps push cancer development and growth.

They say the findings could explain recent, puzzling observations about E-cadherin expression in breast cancer, for example. While loss of E-cadherin is generally considered a harbinger of metastasis, researchers have also found that most breast cancer that has spread retains E-cadherin expression. Ovarian tumors also have been paradoxically found to produce more and more E-cadherin as they grow.

"This surprising finding should compel us all to shift our thinking about E-cadherin," says the study's lead investigator, cancer biologist Panos Z. Anastasiadis, Ph.D. "Up to now, we have all thought that if a tumor loses E-cadherin function, that represents a movement toward metastasis. That makes sense because 50 percent of cancers don't express E-cadherin and they are linked to a worse prognosis.

"But now it appears that E-cadherin expression in a tumor could be responsible for cells growing out of control if the protein is not functioning as it should be."

Dr. Anastasiadis focuses his research on the biological factors involved in cancer metastasis. In this study, he and a research team, which included scientists from Mayo Clinic's campuses in Florida and Minnesota, examined protein expression in glioblastoma cancer cells. Glioblastoma is the most common, as well as the most dangerous, brain cancer.

"Our interest is to understand the pathways that induce glioblastoma to be so invasive," he says. "The problem with this cancer is that the tumors can be very aggressive, and single cancer cells can spread all over the brain."

Among other proteins, the researchers looked at cadherins, of which about 20 are expressed in the brain — more than in any other organ. These are transmembrane proteins that play critical roles in determining how cells bind to each other in a tissue. The researchers expected to find significant amounts of neural cadherin (N-cadherin) in the tumors, but not E-cadherin, which is expressed in epithelial rather that normal brain tissue.

In epithelial tissue, loss of E-cadherin usually represents a switch in cell behavior known as epithelial-mesenchymal transition (EMT). In EMT, cells that had been tightly bound to each other loosen up, due to loss of E-cadherin, and other proteins — including other members of the cadherin superfamily — then promote migration of individual cells away from a cancer cluster. Drugs are being developed that target this EMT switch, says Dr. Anastasiadis.

Given these facts, the researchers say that what they found surprised them. While N-cadherin was expressed in most human brain tumor cell lines — and N-cadherin is potentially oncogenic — some also expressed E-cadherin. They also found those cells that expressed E-cadherin acted more aggressively than brain cancer that did not express the protein. The researchers then validated their findings in animal studies. Finally, they performed an experiment in which they removed E-cadherin expression from glioblastoma cells and found these cells had a reduced ability to move, and grew at a much slower pace.

"E-cadherin expressed in these glioblastomas did not function to keep cells stuck together. Instead, they promoted tumor growth and migration," Dr. Anastasiadis says. "This is the complete opposite of what we have known about E-cadherin. For some reason, in these brain cells, E-cadherin expression is linked to aggressive cell behavior and poor prognosis."

The findings suggest "cadherins, as a whole class of proteins, need to be studied in more detail," he says. "E-cadherin expressed in glioblastoma functioned like an oncogene and it could be doing the same in many breast, ovarian, and other tumors found elsewhere in the body.

"Understanding what causes the switch in E-cadherin function from a tumor suppressor to an oncogene, and how to block it, will be critical," concludes Dr. Anastasiadis. "But the bottom line is that we cannot view E-cadherin simply as a tumor suppressor anymore."

The study was funded by the National Institutes of Health, the Accelerate Brain Cancer Cure Foundation, and a Daniel Foundation training grant. Co-authors from Mayo Clinic's sites in Florida and Minnesota include Laura Lewis-Tuffin, Ph.D., Fausto Rodriquez, M.D., Caterina Giannini, M.D., Ph.D., Bernd Scheithauer, Brian Necela, Ph.D., and Jann Sarkaria, M.D. The authors declare no conflicts of interest.

About Mayo Clinic

For more than 100 years, millions of people from all walks of life have found answers at Mayo Clinic. These patients tell us they leave Mayo Clinic with peace of mind knowing they received care from the world's leading experts. Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. At Mayo Clinic, a team of specialists is assembled to take the time to listen, understand and care for patients' health issues and concerns. These teams draw from more than 3,700 physicians and scientists and 50,100 allied staff that work at Mayo Clinic's campuses in Minnesota, Florida, and Arizona; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. To best serve patients, Mayo Clinic works with many insurance companies, does not require a physician referral in most cases and is an in-network provider for millions of people. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your general health information.

Kevin Punsky | EurekAlert!
Further information:
http://www.mayo.edu

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>